You are here

Vaccine Against Primate Immunodeficiency Retroviruses

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 AI37390-01,
Agency Tracking Number: 29106
Amount: $97,549.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1650 Borel Place, Suite 234
San Mateo, CA 94402
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Vera Byers
 () -
Business Contact
Phone: () -
Research Institution

SIV infection of rhesus macaques serves as a valuable model for HIV infection in humans. Both virusthrough the CD4 T-lymphocyte receptor and are infectious and cytopathic for CD4+ T-lymphocytes and mviruses are genetically closely related: SIV shares approximately 50 percent homology with HIV-1 andhomology with HIV-2. In SIV- infected rhesus macaques, as in HIV-infected humans, a predominantly asinfection is followed by a disease onset which is characterized by decreasing CD4+ T-lymphocytes, into opportunistic infections and increasing viral load. Due to the ability to challenge vaccinated mapathogenic virus, the SIV; rhesus macaque model system is invaluable in the development of HIV vaccimore rapid disease onset in this animal model (less than 2 years as opposed to l0 years with HIV infenables vaccine efficacy to be determined relatively quickly (for review see: Gardner and Hu, l99l).under ideal laboratory conditions, the development of a safe vaccine that will protect against SIV irigorous conditions has remained elusive. A complete vaccine would induce cytotoxic T lymphocytes (Cfour major antigenic proteins in SIV and humoral immunity against the envelope coat protein. Prelimimacaques have demonstrated that use of recombinant BCG can efficiently generate such antigen specifiproject will verify these results as well as examine the other types of immunity resulting from immuvectors. It will also validate the use of a new biological adjuvant to serve as a safe boosting agen

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government